Whitehawk Therapeutics, Inc. (WHWK)
NASDAQ: WHWK · Real-Time Price · USD
4.160
+0.050 (1.22%)
At close: Jun 26, 2026, 4:00 PM EDT
4.160
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
Company Description
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021.
Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Whitehawk Therapeutics, Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | David Lennon |
Contact Details
Address: 2 Headquarters Plaza, East Building Morristown, New Jersey 07960 United States | |
| Phone | 551 321 2234 |
| Website | ir.whitehawktx.com |
Stock Details
| Ticker Symbol | WHWK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422142 |
| CUSIP Number | 00032Q104 |
| ISIN Number | US00032Q1040 |
| Employer ID | 61-1547850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David J. Lennon Ph.D. | President, Chief Executive Officer and Director |
| Dr. Neil P. Desai Ph.D. | Founder and Director |
| Scott M. Giacobello CPA | Chief Financial Officer, Treasurer, Investor Relations and Corporate Communications |
| Bryan Ball | Chief Technical Operations Officer |
| Dr. David Dornan Ph.D. | Chief Scientific Officer |
| Stephen M. Rodin J.D. | Senior Vice President of Legal and General Counsel |
| Dr. Margaret Han Dugan M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 12, 2026 | 8-K | Current Report |
| Jun 9, 2026 | EFFECT | Notice of Effectiveness |
| May 29, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 21, 2026 | 8-K | Current Report |
| May 18, 2026 | SCHEDULE 13D/A | Filing |
| May 14, 2026 | SCHEDULE 13D/A | Filing |
| May 13, 2026 | 8-K | Current Report |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |